

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 3

Attorney Docket No. 0344.210US

RECEIVED  
CENTRAL FAX CENTER

JUL 11 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all prior versions and listings of claims in the application:

1-138. (Cancelled)

139. (Currently Amended) An isolated or recombinant polypeptide comprising a polypeptide sequence that has at least 97% 96% sequence identity to a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4, wherein said isolated or recombinant polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

2 140. (Currently Amended) An isolated or recombinant The polypeptide of claim 139, wherein the polypeptide comprises comprising a polypeptide sequence that has at least about 97% 96% sequence identity to a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4, wherein said polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

3 141. (Currently Amended) An isolated or recombinant The polypeptide of claim 139, wherein the polypeptide comprises comprising a polypeptide sequence that has at least about 96% sequence identity to the polypeptide sequence of SEQ ID NO:4, wherein said polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

4 142. (Currently Amended) The polypeptide of claim 139, wherein the polypeptide comprises a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4.

5 143. (Currently Amended) The polypeptide of claim 140, wherein the polypeptide comprises a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4.

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 4

Attorney Docket No. 0344.210US

*b*  
~~144.~~ (Previously Presented) The polypeptide of claim *141*, wherein the polypeptide comprises the polypeptide sequence of SEQ ID NO:4.

*f*  
~~145.~~ (Previously Presented) The polypeptide of claim *139*, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

*b*  
~~146.~~ (Previously Presented) The polypeptide of claim *139*, wherein the polypeptide induces a T cell response against human EpCAM.

*g*  
~~147.~~ (Previously Presented) The polypeptide of claim *146*, wherein the polypeptide T cell proliferation response against human EpCAM.

*b*  
~~148.~~ (Previously Presented) The polypeptide of claim *139*, wherein the polypeptide induces production of at least one cytokine.

*h*  
~~149.~~ (Previously Presented) The polypeptide of claim *139*, wherein the at least one cytokine is interferon-gamma.

*i*  
~~150.~~ (Previously Presented) The polypeptide of claim *139*, wherein the polypeptide is glycosylated and/or pegylated.

*j*  
~~151.~~ (Previously Presented) The polypeptide of claim *139*, wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production of one or more cytokines.

*k*  
~~152.~~ (Previously Presented) The polypeptide of claim *140*, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 5

Attorney Docket No. 0344.210US

153. (Previously Presented) The polypeptide of claim 140, wherein the polypeptide induces a T cell response against human EpCAM.

164. (Previously Presented) The polypeptide of claim 140, wherein the polypeptide induces production of at least one cytokine.

175. (Previously Presented) The polypeptide of claim 140, wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production of one or more cytokines.

186. (Previously Presented) The polypeptide of claim 141, wherein the immune response comprises at least one of an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof, induce a T cell response against human EpCAM, or induce production of at least one cytokine.

197. (Previously Presented) A composition comprising the polypeptide of claim 139 and a carrier, diluent, or excipient.

208. (Previously Presented) The composition of claim 197, wherein the composition further comprises at least one adjuvant, immunomodulatory polypeptide, or cytokine, or any combination thereof.

219. (New) The polypeptide of claim 139, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4.

220. (New) The polypeptide of claim 140, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4.

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 6

Attorney Docket No. 0344.210US

*23*  
~~161.~~ (New) The polypeptide of claim ~~141~~<sup>3</sup>, wherein the polypeptide comprises a polypeptide sequence that has at least 97% sequence identity to the polypeptide sequence of SEQ ID NO:4.

*24*  
~~162.~~ (New) The polypeptide of claim ~~161~~<sup>23</sup>, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to the polypeptide sequence of SEQ ID NO:4.

*25*  
~~163.~~ (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~139~~<sup>1</sup>.

*26*  
~~164.~~ (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~140~~<sup>2</sup>.

*27*  
~~165.~~ (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~141~~<sup>3</sup>.

~~166.~~ (New) A nucleic acid that encodes the polypeptide of claim 139.

~~167.~~ (New) A nucleic acid that encodes the polypeptide of claim 140.

~~168.~~ (New) A nucleic acid that encodes the polypeptide of claim 141.